Guided Therapeutics Inc.
http://www.guidedinc.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Guided Therapeutics Inc.
Patents And LOEs Poised To Be Hot Q2 Topics
Novartis and Johnson & Johnson will be the first two big pharmas to release second quarter financial results, and both have faced recent patent case developments for top-selling drugs.
Promore’s Enserpetide Has Phase II Setback In Scar Prevention, Focus Shifts To Ropocamptide
The Swedish firm’s lead program has unexpectedly disappointed in a Phase II scar prevention trial, prompting it to turn its efforts to its only other clinical asset for the treatment of chronic wounds.
Finance Watch: As Exit Values Rise, More Money Flows Into VC Investments
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.
Deals Shaping the Medical Industry, January 2018
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.
Company Information
- Industry
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
-
Digital Health
- Artificial Intelligence
- Other Names / Subsidiaries
-
- SpectRx
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice